A Preliminary Study for the Intervention of an N-of-1 Protocol For Medication Optimization
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Change in participant's confidence regarding their preference to continue or discontinue beta-blocker, as assessed by qualitative interviews
研究概览
简要总结
Investigators will determine whether N-of-1 trials, as a pragmatic, participant-centered approach to medication optimization that can overcome key barriers of deprescribing, can lead to increased participant confidence regarding their preference to continue or discontinue beta-blockers in older adults with Heart Failure with Preserved Ejection Fraction (HFpEF).
详细描述
This is an unblinded NIH Stage I of Behavioral Intervention Development trial, using serial multiple-period single participant crossover design. Investigators will enroll 20 participants, conducting an N-of-1 trial in each. The intervention is a two-arm crossover withdrawal/reversal design (On [A] vs. Off [B]) with up to 6 periods, each period lasting up to 6 weeks. The sequence of treatment will be randomized to either ABAB or BABA. Each participant will have the option to participate in additional (no more than 6) periods if they wish to gather more data. The intervention drug will be beta-blockers, previously prescribed to the participants by their physician. The investigators have developed a titration algorithm, where during the On period (A), participants will be on their baseline beta-blocker dose (or the highest dose they can safely tolerate). During the Off period (B), their beta-blockers will be down-titrated and subsequently discontinued (or at the lowest dose they can safely tolerate); we will decrease the dose of the beta-blocker by 50% every week regardless of which beta-blocker they are on. When returning to On, from Off, we will up-titrate by 50% until reaching their home dose (or the highest dose they can safely tolerate).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ambulatory adults age ≥ 65 years with HFpEF, according to ACC/AHA guidelines (signs and symptoms of heart failure AND ejection fraction ≥ 50%)
- •Taking beta-blocker
排除标准
- •Alternate cause(s) of HFpEF Syndrome:
- •Severe aortic stenosis
- •Moderate-severe mitral stenosis
- •Constrictive pericarditis
- •High output HF
- •Infiltrative cardiomyopathy
- •Other compelling indication(s) for beta-blocker
- •Prior EF < 50%
- •Hypertrophic cardiomyopathy
- •Acute coronary syndrome, myocardial infarction, or coronary artery bypass surgery in prior 3 years
- •History of ventricular tachycardia/arrhythmia
- •Atrial arrhythmia with hospitalization for rapid ventricular response, prior 1 year
- •Heart rate >100 bpm within the prior 3 months
- •Atrial arrhythmia with ventricular rate >90 per minute in the prior 3 months
- •Systolic blood pressure readings >160 mmHg within the prior 3 months, unless classified as white coat hypertension/effect (and home blood pressures below 140 mmHg)
- •Non-cardiac indications (e.g., migraine prevention, anxiety symptom management, hyperthyroidism, essential tumor reduction)
- •Clinical instability (N-of-1 trials are appropriate for stable conditions only)
- •Decompensated heart failure
- •Hospitalization in the past 30 days
- •Medication changes or procedures in the prior 14 days that could confound observations/data at PI discretion
- •Anticipated medication changes or procedures in subsequent 3 months that could confound observations/data at PI discretion
- •Clinical instability from other medical issues
- •Estimated life expectancy < 6 months
- •Moderate-severe dementia or psychiatric disorder precluding informed consent
- •Language barrier that will preclude informed consent and ability to comprehend study procedures
- •Non-compliance or inability to complete study procedures
- •Enrollment in a clinical trial not approved for co-enrollment
- •Any condition that, in the Principal Investigator or treating physician's opinion, makes the patient unsuitable for study participation
研究组 & 干预措施
Beta-Blocker ABAB Sequence
This arm will follow an ABAB sequence: ON beta-blockers (A) and OFF beta-blockers (B). Participants start with their home beta-blocker dose in Period 1 (A), and then switch to Period 2 (B), where the dose is slowly reduced until they are off their beta-blocker (or the lowest tolerable dose). Participants are then asked if they have enough information to clarify their preference about continuing or discontinuing their beta-blocker. Participants can choose to engage in 2-6 periods based on whether they need more information to make a preference. These extra phases follow the same ON-OFF pattern (ABABAB), meaning if the participant chooses to continue into Period 3 (A), the study team will restart the participant's beta-blocker, and slowly up-titrate until they reach their home dose, or their highest tolerable dose. This continues until the participant has enough information to clarify their preference about their beta-blocker, with a limit of 6 periods.
干预措施: Beta blocker (Drug)
Beta-Blocker BABA Sequence
This arm will follow a BABA sequence: OFF beta-blockers (B) and ON beta-blockers (A). Participants start Period 1 (B) by slowly reducing the participant's beta-blocker home dose by 50% each week until they are off (or the lowest tolerable dose), then switch to Period 2 (A), where they restart their beta-blocker and slowly up-titrate until they reach their home dose (or the highest tolerable dose). Participants are then asked if they have enough information to clarify their preference about continuing or discontinuing their beta-blocker. Participants can choose to engage in 2-6 periods based on whether they need more information. The extra phases follow the same OFF-ON pattern (BABABA), meaning if they choose to continue into Period 3 (B), the participant will slowly reduce their beta-blocker until they are off (or the lowest tolerable dose). This continues until the participant has enough information to clarify their preference about their beta-blocker, with a max of 6 periods.
干预措施: Beta blocker (Drug)
结局指标
主要结局
Change in participant's confidence regarding their preference to continue or discontinue beta-blocker, as assessed by qualitative interviews
时间窗: From the date of their baseline visit to the date of their last follow-up interview, assessed up to 88 weeks.
Qualitative interviews will be conducted to assess the change in confidence through their experience participating in N-of-1 trials. Directed content analysis methods will be used to develop relevant categories and themes from interview transcript data. Transcripts will be coded and analyzed by two team members, consulting additional members to establish consensus where needed. Inter-rater reliability between coders will be established using Cohen's Kappa score.
Change in participant decision-confidence, as measured by the Decisional Conflict Scale (DCS)
时间窗: From the date of their baseline visit, to the date of their end of intervention visit, assessed up to 36 weeks.
Measures participant perceptions of uncertainty in decision-making, factors contributing to uncertainty, and effective decision-making. A set of 16 questions with responses ranging from "strongly agree" = (0) to "strongly disagree" = (4). Scores are summed together to produce an overall score between 0 and 100. Lower scores indicate feeling informed and low decisional conflict whereas higher scores indicate feelings of uncertainty and high decisional conflict.
次要结局
- Features of a feasible and pragmatic protocol for deprescribing N-of-1 trials in participants with Heart Failure with Preserved Ejection Fraction, as measured by qualitative interviews.(From the date of their baseline visit to the date of their last follow-up interview, assessed up to 88 weeks.)
- Change in participants feeling informed through an N-of-1 protocol, as measured by the Decisional Conflict sub-scale(From the date of their baseline visit, to the date of their end of intervention visit, assessed up to 36 weeks.)
- Change in participants feeling uncertainty through an N-of-1 protocol, as measured by the Decisional Conflict sub-scale(From the date of their baseline visit, to the date of their end of intervention visit, assessed up to 36 weeks.)
- Change in participants feeling supported through an N-of-1 protocol, as measured by the Decisional Conflict sub-scale(From the date of their baseline visit, to the date of their end of intervention visit, assessed up to 36 weeks.)
- Change in participants decision effectiveness through an N-of-1 protocol, as measured by the Decisional Conflict sub-scale(From the date of their baseline visit, to the date of their end of intervention visit, assessed up to 36 weeks.)
- Change in participant activation through an N-of-1 protocol, as assessed by the Patient Activation Measure (PAM)(From the date of their baseline visit, to the date of their end of intervention visit, assessed up to 36 weeks.)
- Change in shared decision making through an N-of-1 protocol, as measured by the 9-item Shared Decision-Making Questionnaire(From the date of their baseline visit, to the date of their end of intervention visit, assessed up to 36 weeks.)